Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease
- DOI
- 10.1038/s41598-021-97236-0
- Published
- 2021-09-30
- Container
- Scientific Reports
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1038/s41598-021-97236-0,
title = {Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease},
author = {Kevin J. Roberts and Marion F. Cubitt and Timothy M. Carlton and Lurdes Rodrigues-Duarte and Luana Maggiore and Ray Chai and Simon Clare and Katherine Harcourt and Thomas T. MacDonald and Keith P. Ray and Anna Vossenkämper and Michael R. West and J. Scott Crowe},
year = {2021},
journal = {Scientific Reports},
doi = {10.1038/s41598-021-97236-0},
url = {https://doi.org/10.1038/s41598-021-97236-0}
}RIS
TY - JOUR TI - Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease AU - Kevin J. Roberts AU - Marion F. Cubitt AU - Timothy M. Carlton AU - Lurdes Rodrigues-Duarte AU - Luana Maggiore AU - Ray Chai AU - Simon Clare AU - Katherine Harcourt AU - Thomas T. MacDonald AU - Keith P. Ray AU - Anna Vossenkämper AU - Michael R. West AU - J. Scott Crowe PY - 2021 JO - Scientific Reports DO - 10.1038/s41598-021-97236-0 UR - https://doi.org/10.1038/s41598-021-97236-0 ER -
APA
Roberts, K. J., Cubitt, M. F., Carlton, T. M., Rodrigues-Duarte, L., Maggiore, L., Chai, R., Clare, S., Harcourt, K., MacDonald, T. T., Ray, K. P., Vossenkämper, A., West, M. R., & Crowe, J. S. (2021). Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease. Scientific Reports. https://doi.org/10.1038/s41598-021-97236-0
Source records
- crossref · retrieved 2026-09-26T19:42:14.225Z